

wherein

X and Z each represent CH or N;

R^1 , R^2 , and R^3 , which may be the same or different, represent a hydrogen atom, C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, nitro, or amino, which C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl are optionally substituted by a halogen atom; hydroxyl; C_{1-4} alkoxy; C_{1-4} alkoxy carbonyl; amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl or C_{1-4} alkoxy; group $R^{12}R^{13}N-C(=O)-O-$ wherein R^{12} and R^{13} , which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl which alkyl is optionally substituted by hydroxyl or C_{1-4} alkoxy; or group $R^{14}-(S)_m-$ wherein R^{14} represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by C_{1-4} alkyl and m is 0 or 1;


R^4 represents a hydrogen atom;

R^5 , R^6 , R^7 , and R^8 , which may be the same or different, represent a hydrogen atom, a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, nitro, or amino, provided that R^5 , R^6 , R^7 , and R^8 do not simultaneously represent a hydrogen atom;

R^9 and R^{10} , which may be the same or different, represent a hydrogen atom, C_{1-6} alkyl, or C_{1-4} alkyl carbonyl, the alkyl portion of which C_{1-6} alkyl or C_{1-4} alkyl carbonyl is optionally substituted by a halogen atom; C_{1-4} alkoxy; amino which is optionally substituted by C_{1-4} alkyl optionally substituted by C_{1-4} alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and

B¹ R¹¹ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl (which C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl each are optionally substituted by a halogen atom or C₁₋₆ alkoxy), or R¹⁵-(CH₂)_n- wherein n is an integer of 0 to 4 and R¹⁵ represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C₁₋₆ alkyl, or C₁₋₆ alkoxy and is optionally condensed with another saturated or unsaturated three- to seven-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

B² 5. (Amended) A compound represented by formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:



wherein

X represents CH or N;

R²¹ and R²², which may be the same or different, represent unsubstituted C₁₋₆ alkoxy or group R³¹-(CH₂)_p-O- wherein R³¹ represents a halogen atom, hydroxyl, C₁₋₄ alkoxy, C₁₋₄ alkoxycarbonyl, amino on which one or two hydrogen atoms are optionally substituted by C₁₋₄ alkyl optionally substituted by hydroxyl or C₁₋₄ alkoxy, group R¹²R¹³N-C(=O)-O- wherein R¹² and R¹³, which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl which alkyl is optionally substituted by hydroxyl or C₁₋₄ alkoxy, or group R¹⁴-(S)_m- wherein R¹⁴ represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by C₁₋₄ alkyl and m is 0 or 1; and p is an integer of 1 to 6;

B² R²³, R²⁴, R²⁵, and R²⁶, which may be the same or different, represent a hydrogen atom, a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, nitro, or amino, provided that R²³, R²⁴, R²⁵, and R²⁶ do not simultaneously represent a hydrogen atom;

R²⁷ and R²⁸, which may be the same or different, represent a hydrogen atom, C₁₋₆ alkyl, or C₁₋₄ alkylcarbonyl, the alkyl portion of which C₁₋₆ alkyl or C₁₋₄ alkylcarbonyl is optionally substituted by a halogen atom; C₁₋₄ alkoxy; amino which is optionally substituted by C₁₋₄ alkyl optionally substituted by C₁₋₄ alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and

R²⁹ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl (which C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl each are optionally substituted by a halogen atom or C₁₋₄ alkoxy), or R³²-(CH₂)_q- wherein q is an integer of 0 to 4 and R³² represents a saturated or unsaturated six-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C₁₋₄ alkyl, or C₁₋₄ alkoxy and is optionally condensed with another saturated or unsaturated five- or six-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

B³ 51. (Twice Amended) A method for treating a disease selected from the group consisting of malignant tumor, diabetic retinopathy, chronic rheumatism, psoriasis, and atherosclerosis, comprising the step of administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, to mammals.

Please add the following claims.

B⁴ --53. (New) The method of claim 51, wherein the disease is Kaposi's sarcoma.
54. (New) The compound according to claim 1, wherein R¹ represents a hydrogen atom and R² and R³ represent unsubstituted C₁₋₄ alkoxy.

55. (New) The compound according to claim 1, wherein R^5 , R^7 , and R^8 represent a hydrogen atom and R^6 represents a chlorine atom.

B4 56. (New) The compound according to claim 1, wherein R^{14} represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

57. (New) The compound according to claim 1, wherein R^{15} represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

58. (New) The compound according to claim 1, wherein R^1 represents a hydrogen atom, R^2 and R^3 represent unsubstituted C_{1-4} alkoxy, R^5 , R^7 , and R^8 represent a hydrogen atom, R^6 represents a chlorine atom, R^9 and R^{10} represent a hydrogen atom, and R^{11} represents $R_{15}-(CH_2)_n$ - wherein n represents 0 (zero) and R_{15} represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

59. (New) The compound according to claim 1, which is N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'-propylurea.—

SUPPORT FOR THE AMENDMENTS

Claims 1 and 5 have been amended for clarity. Newly-added Claim 53 is supported by original Claim 51. The amendment to Claim 51 and newly added Claims 54-59 are supported by the specification at pages 1-200, especially pages 4-6 and 91. No new matter is believed to have been added to this application by these amendments.

REMARKS

Claims 1-48 and 51-59 are pending. Favorable reconsideration is respectfully requested.